iBio, Inc.
IBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001420720
No open-market purchases or sales by iBio, Inc. insiders were filed in the last 90 days; 55 institutions reported holding it in 13F filings for Q2 2026, worth $60.8M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 55
- 13F valueReported value at the end of Q2 2026
- $60.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding IBIO, Q2 2026
No superinvestor reported holding IBIO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by iBio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 (view filing) | Mar 26 | 1 day | Banjak MarcChief Legal Officer | PPurchase | +13.9K | $1.65 | +$23.0K | +125.9%25.0K after | 2 lots |
| Mar 23, 2026 (view filing) | Mar 19 | 4 days | Duran FelipeChief Financial Officer | PPurchase | +24.8K | $2.02 | +$50.2K | +223.0%36.0K after | |
| Mar 23, 2026 (view filing) | Mar 19 | 4 days | Brenner MartinSee Remarks | PPurchase | +12.3K | $2.02 | +$24.9K | +67.4%30.7K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Duran FelipeChief Financial Officer | PPurchase | +9.19K | $2.72 | +$25.0K | +471.8%11.1K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Brenner MartinSee Remarks | PPurchase | +9.19K | $2.72 | +$25.0K | +100.7%18.3K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Banjak MarcChief Legal Officer | PPurchase | +9.19K | $2.72 | +$25.0K | +490.2%11.1K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Arkowitz DavidDirector | PPurchase | +18.4K | $2.72 | +$50.0K | New position18.4K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Clark William DDirector | PPurchase | +1.84K | $2.72 | +$5.00K | New position1.84K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Parada Antonio Bernardino GuimaraesDirector | PPurchase | +183.8K | $2.72 | +$500.0K | New position183.8K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Sender GaryDirector | PPurchase | +9.19K | $2.72 | +$25.0K | New position9.19K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in iBio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 4,007,881 | $7.01M | 0.34% | +900,681+29.0% | Added |
| Cormorant Asset Management, LP | 3,570,000 | $6.25M | 0.32% | +3,570,000 | New |
| Silverarc Capital Management, LLC | 3,520,490 | $6.16M | 0.69% | +3,294,490+1,457.7% | Added |
| Vestal Point Capital, LP | 2,600,000 | $4.55M | 0.11% | +2,600,000 | New |
| Vanguard Capital Management LLC | 2,098,151 | $3.67M | 0.00% | +1,009,852+92.8% | Added |
| Frazier Life Sciences Management, L.P. | 1,953,467 | $3.42M | 0.07% | 00.0% | Unchanged |
| Ensign Peak Advisors, Inc | 1,832,457 | $3.21M | 0.01% | +1,832,457 | New |
| Woodline Partners LP | 1,776,547 | $3.11M | 0.01% | +1,776,547 | New |
| Millennium Management LLC | 1,651,473 | $2.89M | 0.00% | +101,623+6.6% | Added |
| Citadel Advisors LLC | 1,384,029 | $2.42M | 0.00% | +427,600+44.7% | Added |